
GH Research PLC (NASDAQ:GHRS – Free Report) – Analysts at HC Wainwright increased their FY2026 EPS estimates for shares of GH Research in a report issued on Tuesday, November 17th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($1.00) per share for the year, up from their previous estimate of ($1.14). HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for GH Research’s current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for GH Research’s Q4 2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.32) EPS, Q2 2027 earnings at ($0.37) EPS, Q4 2027 earnings at ($0.47) EPS, FY2027 earnings at ($1.59) EPS, FY2028 earnings at ($1.70) EPS, FY2029 earnings at ($1.90) EPS and FY2030 earnings at ($0.40) EPS.
GHRS has been the topic of several other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a report on Thursday, October 15th. Needham & Company LLC raised their price target on GH Research from $32.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Guggenheim boosted their price target on GH Research from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday. Wall Street Zen upgraded GH Research from a “sell” rating to a “hold” rating in a research note on Saturday, November 14th. Finally, Cantor Fitzgerald increased their price objective on GH Research from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.
Get Our Latest Research Report on GHRS
GH Research Price Performance
Shares of NASDAQ GHRS opened at $18.25 on Thursday. The business has a 50-day moving average of $21.73 and a 200-day moving average of $21.68. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -19.21 and a beta of 1.31. GH Research has a fifty-two week low of $12.04 and a fifty-two week high of $31.44.
GH Research (NASDAQ:GHRS – Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.13.
Institutional Investors Weigh In On GH Research
A number of institutional investors and hedge funds have recently modified their holdings of GHRS. Troluce Capital Advisors LLC lifted its stake in GH Research by 165.4% in the 1st quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock valued at $13,926,000 after purchasing an additional 617,260 shares during the last quarter. Braidwell LP bought a new position in GH Research during the second quarter worth about $5,571,000. Marshall Wace LLP grew its holdings in GH Research by 46.3% during the third quarter. Marshall Wace LLP now owns 68,298 shares of the company’s stock worth $1,604,000 after purchasing an additional 21,601 shares during the period. Squarepoint Ops LLC bought a new position in GH Research during the second quarter worth about $495,000. Finally, China Universal Asset Management Co. Ltd. increased its position in GH Research by 30.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 17,525 shares of the company’s stock worth $432,000 after buying an additional 4,106 shares during the last quarter. 56.90% of the stock is owned by institutional investors.
Recent GH Research Headlines
These are some of the GHRS headlines that stood out recently:
- Positive Sentiment: Guggenheim raised its price target to $46 from $40 and kept a Buy rating, signaling continued confidence in the shares. Guggenheim analyst information
- Neutral Sentiment: HC Wainwright’s outlook was not uniformly better: its Q4 2027 EPS estimate edged lower to ($0.47) from ($0.46). Its $55 target is also below its previous $65 target, though the firm continues to rate GH Research Buy.
- Negative Sentiment: A report linked GH Research’s shares’ recent weakness to an analyst downgrade; the provided report does not identify the analyst or give further details. GH Research shares down on analyst downgrade
About GH Research
GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.
Featured Stories
- Five stocks we like better than GH Research
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.
